During the last session, Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s traded shares were 0.53 million, with the beta value of the company hitting 1.44. At the end of the trading day, the stock’s price was $2.85, reflecting an intraday loss of -2.06% or -$0.06. The 52-week high for the SNOA share is $9.37, that puts it down -228.77 from that peak though still a striking 11.58% gain since the share price plummeted to a 52-week low of $2.52. The company’s market capitalization is $3.82M, and the average intraday trading volume over the past 10 days was 1.19 million shares, and the average trade volume was 327.46K shares over the past three months.
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) trade information
Sonoma Pharmaceuticals Inc (SNOA) registered a -2.06% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.06% in intraday trading to $2.85, hitting a weekly high. The stock’s 5-day price performance is 11.32%, and it has moved by -1.72% in 30 days. Based on these gigs, the overall price performance for the year is -18.48%. The short interest in Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) is 79898.0 shares and it means that shorts have 0.22 day(s) to cover.
Sonoma Pharmaceuticals Inc (SNOA) estimates and forecasts
Statistics show that Sonoma Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Sonoma Pharmaceuticals Inc (SNOA) shares have gone down -27.77% during the last six months, with a year-to-date growth rate more than the industry average at 47.37% against 16.60. In the rating firms’ projections, revenue will increase 21.48% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.06M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 4.44M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.14M and 3.44M respectively. In this case, analysts expect current quarter sales to grow by 29.38% and then jump by 29.11% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 47.04%. While earnings are projected to return 91.29% in 2024.
SNOA Dividends
Sonoma Pharmaceuticals Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s Major holders
Sonoma Pharmaceuticals Inc insiders own 1.51% of total outstanding shares while institutional holders control 2.42%, with the float percentage being 2.45%. CITADEL ADVISORS LLC is the largest shareholder of the company, while 19.0 institutions own stock in it. As of 2024-06-30, the company held over 0.2 million shares (or 1.2504% of all shares), a total value of $41412.0 in shares.
The next largest institutional holding, with 86644.0 shares, is of GEODE CAPITAL MANAGEMENT, LLC’s that is approximately 0.5551% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $18385.0.
Also, the Mutual Funds coming in first place with the largest holdings of Sonoma Pharmaceuticals Inc (SNOA) shares are Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund . Data provided on Sep 30, 2024 indicates that Fidelity Extended Market Index Fund owns about 5.44 shares. This amounts to just over 0.41 percent of the company’s overall shares, with a $15512.0 market value. The same data shows that the other fund manager holds slightly less at 1.26, or about 0.09% of the stock, which is worth about $3593.0.
